Live market news
Stocks
1801.HK

1801.HK

1801.HKStock

Latest news on 1801.HKranked by Oyticker for market impact

45Impact
Positive28 Sept 2026 · 00:01 UTC · Global · Medium term
Innovent expands Phase 3 MarsLight-11 trial of IBI363/TAK-928 to non-squamous NSCLC
Innovent Biologics announced expansion of its global Phase 3 MarsLight-11 study to include patients with non-squamous NSCLC, broadening the patient population for its IL-2/PD-1 bispecific fusion protein candidate in immunotherapy-resistant disease.
1801.HKBiopharmaceuticalsOncology

Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.

Latest news on 1801.HKranked by Oyticker for market impact

Innovent expands Phase 3 MarsLight-11 trial of IBI363/TAK-928 to non-squamous NSCLC